PACB
Pacific Biosciences of California
1.60$
+2.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.0% | -4.4% | -9.6% | -3.9% | -13.1% | -31.7% | -4.1% | -2.7% | -2.4% | -0.2% | -3.9% | |
| – | -15.9% | -8.8% | -7.2% | -7.0% | -15.2% | -10.2% | -7.1% | -4.6% | -4.9% | -1.5% | -8.4% | |
| – | -53.3% | -57.5% | +29.9% | -21.6% | -29.0% | +5.7% | -6.3% | +3.0% | +12.8% | -11.6% | +8.4% | |
| – | -17.7% | -11.0% | -9.3% | -7.6% | -17.2% | -12.0% | -8.3% | -5.1% | -6.4% | -1.3% | -14.2% | |
| – | +20.1% | -17.2% | +7.0% | -9.4% | -6.3% | +15.0% | +1.9% | -5.1% | +15.8% | -17.2% | +6.0% | |
| – | -17.0% | +18.8% | +1.9% | -4.2% | -10.6% | -8.1% | -0.3% | -1.3% | -7.3% | +3.5% | +19.7% | |
| – | -0.3% | +0.0% | -20.2% | +0.0% | -13.9% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -1.1% | -1.5% | -1.5% | -1.5% | -10.7% | -95.3% | -5.6% | -5.9% | -6.3% | -6.7% | -7.2% | |
| – | -7.9% | -2.3% | -0.4% | -2.0% | -24.4% | +2.0% | -0.7% | +0.4% | +1.5% | +0.2% | +0.6% | |
| – | -48.3% | -23.2% | +7.5% | -23.5% | +10.5% | +0.5% | -10.3% | +5.8% | -13.9% | +20.1% | +5.3% | |
| – | +6.6% | -3.1% | +27.8% | -14.5% | -6.1% | -75.9% | -70.9% | +415.1% | -87.6% | -38.2% | +394.9% | |
| – | -6.5% | +39.5% | -16.7% | -31.0% | +37.5% | -15.4% | +7.3% | +8.7% | +26.9% | -34.5% | +41.3% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | -27.5% | -0.2% | +0.0% | -0.2% | +0.0% | -0.2% | +0.0% | |
| – | -8.2% | -7.5% | -24.1% | -8.0% | +11.8% | -81.9% | -32.9% | -41.3% | -85.2% | -55.8% | -1,503.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.8% | +0.9% | +1.0% | +0.2% | +12.4% | -3.3% | +1.1% | +0.2% | +0.4% | +1.3% | +1.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.